• Sati Aarti Department of Pharmacy, Division of Pharmaceutical Sciences, Shri Guru Ram Rai Institute of Technology and Science, Dehradun – 248 001, Uttarakhand, India
  • Bhatt Priyanka Department of Pharmacy, Shri Ram Murti Smarak, College of Engineering and Technology (Pharmacy), Bareilly – 243 202, Uttar Pradesh, India


 Alzheimer’s disease (AD) is a neurodegenerative disorder with relevant unmet therapeutic needs. Both natural aging and AD have been associated with a significant decline in the Omega-3 polyunsaturated fatty acid, docosahexaenoic acid (DHA), and accordingly, administration of DHA has been proposed as a possible treatment for this pathology. DHA and its derivatives like 2-hydroxy DHA-(OHDHA) have a strong therapeutic potential to treat AD. Studies have demonstrated that DHA induced lipid modifications are paralleled with a reduction in amyloid-beta (Αβ) accumulation and full recovery of cognitive impairment. Omega-3 fatty acids also caused alterations in the subcellular distribution of secretases and reduced Αβ-induced tau protein phosphorylation as well. Furthermore, OHDHA enhanced the survival of neuron-like differentiated cells exposed to different insults such as oligomeric Αβ and N-methyl-D-aspartate-mediated neurotoxicity. In conclusion, this review focuses on the pleiotropic effects of Omega-3 fatty acids that might prove beneficial to treat AD.

Keywords: Amyloid beta, Omega-3 fatty acids, Docosahexaenoic acid.

Author Biography

Sati Aarti, Department of Pharmacy, Division of Pharmaceutical Sciences, Shri Guru Ram Rai Institute of Technology and Science, Dehradun – 248 001, Uttarakhand, India
Assistant Professor in Pharmacy Department in SRMSCET Bareilly


1. Rohit BJ. A review on “new treatment strategies for Alzheimer’s disease as neurodegenerative disease and its risk factor cause, symptoms, and treatment at worldwide. Asian J Pharm Clin Res 2016;9:16-22.
2. Kiranjit K, Rajneet K, Manjinder K. Recent advances in Alzheimer’s disease: Causes and treatment. Int J Pharm Pharm Sci 2016;8:8-15.
3. Ahmed HH, Foda FM, et al. Perspective in the treatment of Alzheimer’s disease: Pre-clinical study. Int J Pharm Pharm Sci 2014;6:482-6.
4. Price DL, Sisodia SS, Borchelt DR. Genetic neurodegenerative diseases: The human illness and transgenic models. Science 1998;282:1079-93.
5. Vassar R, Bennet BD. Beta-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1998;286:5440-64.
6. Blennow K, de Leon MJ, Zetterberg H. Alzheimer’s disease. Lancet 2006;368:387-403.
7. Gandy S. Testing the amyloid hypothesis of Alzheimer’s disease in vivo. Lancet Neurol 2010;9:333-5.
8. Gregersen N, Bross P, Andresen BS. The role of chaperone-assisted folding and quality control in inborn errors of metabolism: Protein folding disorders. J Inherit Metab Dis 2001;24:189-212.
9. Tucci P, Bagetta G. How to study neuroprotection? Cell Death Differ 2008;15:1084-5.
10. McGeer PL, McGeer EG. Inflammation of the brain in Alzheimer’s disease: Implications for therapy. J Leukocyte Biol 1999;65:409-15.
11. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying Inflammation in neurodegeneration. Cell 2010;140:918-34.
12. Goodhart RS, Shils ME. Modern Nutrition in Health and Disease. 6th ed. Philadelphia, PA: Lea and Febinger; 1980. p. 134-8.
13. Ellie W, Rolfes SR. Understanding Nutrition. 11th ed. California: Thomson Wadsworth; 2008. p. 154.
14. Burr GO, Burr MM, Miller E. On the nature and role of the fatty acids essential in nutrition (PDF). J Biol Chem 1930;86:587. Available from: [Last retrieved on 2007 Jan 17].14.
15. Deckelbaum RJ, Torrejon C. The omega-3 fatty acid nutritional landscape: Health benefits and sources. J Nutr 2012;142:587S-91.
16. Seo T, Blaner WS, Deckelbaum RJ. Omega-3 fatty acids: Molecular approaches to optimal biological outcomes. Curr Opin Lipidol 2005;16:11-8.
17. Nakuleshwar JD, Sunita J, Suresh J. Microbial production of docosahexaenoic acid (Ω3 Pufa) and their role in human health. Asian J Pharm Clin Res 2010;3:83-6.
18. Deckelbaum RJ, Worgall TS, Seo T. N-3 fatty acids and gene expression. Am J Clin Nutr 2006;83:1520S-5.
19. Qi K, Seo T, Al-Haideri M, Worgall TS, Vogel T, Carpentier YA, et al. Omega-3 triglycerides modify blood clearance and tissue targeting pathways of lipid emulsions. Biochemistry 2002;41:3119-27.
20. Densupsoontorn N, Carpentier YA, Racine R, Murray FM, Seo T, Ramakrishnan R, et al. CD36 and proteoglycan-mediated pathways for (n-3) fatty acid enriched triglyceride-rich particle blood clearance in mouse models in vivo and in peritoneal macrophages in vitro. J Nutr 2008;138:257-61.
21. Murray-Taylor FM, Ho YY, Densupsoontorn N, Chang CL, Deckelbaum RJ, Seo T. N-3, but not n-6 lipid particle uptake requires cell surface anchoring. Biochem Biophys Res Commun 2010;392:135-9.
22. Yaqoob P, Shaikh SR. The nutritional and clinical significance of lipid rafts. Curr Opin Clin Nutr Metab Care 2010;13:156-66.
23. Sudheendran S, Chang CC, Deckelbaum RJ. N-3 vs. Saturated fatty acids: Effects on the arterial wall. Prostaglandins Leukot Essent Fatty Acids 2010;82:205-9.
24. de Urquiza AM, Liu S, Sjöberg M, Zetterström RH, Griffiths W, Sjövall J, et al. Docosahexaenoic acid, a ligand for the retinoid X receptor in mouse brain. Science 2000;290:2140-4.
25. Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, Fan W, et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 2010;142:687-98.
26. Calder PC. N-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 2006;83:S1505-19.
27. Luchtman DW, Song C. Cognitive enhancement by omega-3 fatty acids from child-hood to old age: Findings from animal and clinical studies. Neuropharmacology 2013;64:550-65.
28. Freemantle E, Vandal M, Tremblay-Mercier J, Tremblay S, Blachère JC, Bégin ME, et al. Omega-3 fatty acids, energy substrates, and brain function during aging. Prostaglandins Leukot Essent Fatty Acids 2006;75:213-20.
29. Appleton KM, Rogers PJ, Ness AR. Updated systematic review and meta-analysis of the effects of ῳ-3 long-chain polyunsaturated fatty acids on depressed mood. Am J Clin Nutr 2010;91:757-70.
30. Sublette ME, Hibbeln JR, Galfalvy H, Oquendo MA, Mann JJ. Omega-3 polyunsaturated essential fatty acid status as a predictor of future suicide risk. Am J Psychiatry 2006;163:1100-2.
31. Carpentier YA, Portois L, Malaisse WJ. N-3 fatty acids and the metabolic syndrome. Am J Clin Nutr 2006;83:1499S-1504.
32. Mayurasakorn K, Williams JJ, Ten VS, Deckelbaum RJ. Docosahexaenoic acid: Brain accretion and roles in neuroprotection after brain hypoxia and ischemia. Curr Opin Clin Nutr Metab Care 2011;14:158-67.
33. Yurko-Mauro K. Cognitive and cardiovascular benefits of docosahexaenoic acid in aging and cognitive decline. Curr Alzheimer Res 2010;7:190-6.
34. Kromhout D, Menotti A, Bloemberg B, Aravanis C, Blackburn H, Buzina R, et al. Dietary saturated and trans fatty acids and cholesterol and 25-year mortality from coronary heart disease: The seven countries study. Prev Med 1995;24:308-15.
35. Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): A randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1223-30.
36. Holman RT, Johnson SB, Hatch TF. A case of human linolenic acid deficiency involving neurological abnormalities. Am J Clin Nutr 1982;35:617-23.
37. Holman RT. The slow discovery of the importance of ῳ3 essential fatty acids in human health. J Nutr 1998;128:427S-33.
38. Fitzgerald MJ, Curran JF. Clinical Neuroanatomy and Related Neuroscience. 4th ed. Edinburgh: WB Saunders; 2002.
39. Larsen R, Eilertsen KE, Elvevoll EO. Health benefits of marine foods and ingredients. Biotechnol Adv 2011;29:508-18.
40. Mostofsky DI, Yehuda S, Salem N Jr. Fatty acids: Physiological and behavioral functions. In: Bendich A, editor. Nutrition and Health. Totowa: Humana Press Inc.; 2001.
41. Dagai L, Peri-Naor R, Birk RZ. Docosahexaenoic acid significantly stimulates immediate early response genes and neurite outgrowth. Neurochem Res 2009;34:867-75.
42. Conquer JA, Tierney MC, Zecevic J, Bettger WJ, Fisher RH. Fatty acid analysis of blood plasma of patients with Alzheimer’s disease, other types of dementia, and cognitive impairment. Lipids 2000;35:1305-12.
43. Ikemoto A, Ohishi M, Sato Y, Hata N, Misawa Y, Fujii Y, et al. Reversibility of n-3 fatty acid deficiency-induced alterations of learning behavior in the rat: Level of n-6 fatty acids as another critical factor. J Lipid Res 2001;42:1655-63.
44. Kyle DJ, Schaefer E, Patton G, Beiser A. Low serum docosahexaenoic acid is a significant risk factor for Alzheimer’s dementia. Lipids 1999;34 Suppl: S245.
45. Bourre JM. Dietary omega-3 fatty acids for women. Biomed Pharmacother 2007;61:105-12.
46. Green KN, Martinez-Coria H, Khashwji H, Hall EB, Yurko-Mauro KA, Ellis L, et al. Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-beta and tau pathology via a mechanism involving presenilin 1 levels. J Neurosci 2007;27:4385-95.
47. Green KN, Smith IF, Laferla FM. Role of calcium in the pathogenesis of Alzheimer’s disease and transgenic models. Subcell Biochem 2007;45:507-21.
48. Kiso Y. Pharmacology in health foods: Effects of arachidonic acid and docosahexaenoic acid on the age-related decline in brain and cardiovascular system function. J Pharmacol Sci 2011;115:471-5.
49. Wu A, Ying Z, Gomez-Pinilla F. Docosahexaenoic acid dietary supplementation enhances the effects of exercise on synaptic plasticity and cognition. Neuroscience 2008;155:751-9.
50. Fedorova I, Salem N Jr. Omega-3 fatty acids and rodent behavior. Prostaglandins Leukot Essent Fatty Acids 2006;75:271-89.
51. Su HM. Mechanisms of n-3 fatty acid-mediated development and maintenance of learning memory performance. J Nutr Biochem 2010;21:364-73.
52. Kawakita E, Hashimoto M, Shido O. Docosahexaenoic acid promotes neurogenesis in vitro and in vivo. Neuroscience 2006;139:991-7.
53. Salem N, Litman B, Kim HY, Gawrisch K. Mechanisms of action of docosahexaenoic acid in the nervous system. Lipids 2001;36:945-59.
54. Astarita G, Jung KM, Berchtold NC, Nguyen VQ, Gillen DL, Head E, et al. Deficient liver biosynthesis of docosahexaenoic acid correlates with cognitive impairment in Alzheimer’s disease. PLoS One 2010;5:e12538.
55. Fraser T, Tayler H, Love S. Fatty acid composition of frontal, temporal and parietal neocortex in the normal human brain and in Alzheimer’s disease. Neurochem Res 2010;35:503-13.
56. Arsenault D, Julien C, Tremblay C, Calon F. DHA improves cognition and prevents dysfunction of entorhinal cortex neurons in 3xTg-AD mice. PLoS One 2011;6:e17397.
57. Lim GP, Calon F, Morihara T, Yang F, Teter B, Ubeda O, et al. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J Neurosci 2005;25:3032-40.
58. Grimm MO, Kuchenbecker J, Grösgen S, Burg VK, Hundsdörfer B, Rothhaar TL, et al. Docosahexaenoic acid reduces amyloid β production via multiple pleiotropic mechanisms. J Biol Chem 2011;286:14028-39.
59. Green KN, Martinez-Coria H, Khashwji H, Hall EB, Yurko-Mauro KA, Ellis L, et al. Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-beta and tau pathology via a mechanism involving presenilin 1 levels. J Neurosci 2007;27:4385-95.
60. Freund-Levi Y, Eriksdotter-Jönhagen M, Cederholm T, Basun H, Faxén-Irving G, Garlind A, et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: Omeg AD study: A randomized double-blind trial. Arch Neurol 2006;63:1402-8.
61. Quinn JF, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, Van Dyck C, et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: A randomized trial. JAMA 2010;304:1903-11.
62. Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Wilson RS, et al. Schneider, consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol 2003;60:940-6.
63. Johnson EJ, Schaefer EJ. Potential role of dietary n-3 fatty acids in the prevention of dementia and macular degeneration. Am J Clin Nutr 2006;83:1494S-8.
64. Yurko-Mauro K, McCarthy D, Rom D, Nelson EB, Ryan AS, Blackwell A, et al. Investigators, beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimers Dement 2010;6:456-64.
65. Torres M, Price SL, Fiol-de Roque MA, Marcilla-Etxenike A, Ahyayauch H, Barceló-Coblijn G, et al. Membrane lipid modifications and therapeutic effects mediated by hydroxydocosahexaenoic acid on Alzheimer’s disease. Biochim Biophys Acta 2014;1838:1680-92.
66. Fiol-de Roque MA, Gutierrez-Lanza R, Terés S, Torres M, Barceló P, Rial RV, et al. Cognitive recovery and restoration of cell proliferation in the dentate gyrus in the 5XFAD transgenicmice model of Alzheimer’s disease following 2-hydroxy-DHA treatment. Biogerontology 2013;14:763-75.
67. Kiecolt-Glaser JK, Belury MA, Andridge R, Malarkey WB, Hwang BS, Glaser R, et al. Omega-3 supplementation lowers inflammation in healthy middle-aged and older adults: A randomized controlled trial. Brain Behav Immun 2012;26:988-95.
68. Im DS. Omega-3 fatty acids in anti-inflammation (pro-resolution) and GPCRs. Prog Lipid Res 2012;51:232-7.
69. Kiecolt-Glaser JK, Belury MA, Andridge R, Malarkey WB, Glaser R. Omega-3 supplementation lowers inflammation and anxiety in medical students: A randomized controlled trial. Brain Behav Immun 2011;25:1725-34.
70. Ho L, van Leeuwen R, Witteman JC, van Duijn CM, Uitterlinden AG, Hofman A, et al. Reducing the genetic risk of age-related macular degeneration with dietary antioxidants, zinc, and omega-3 fatty acids: The Rotterdam study. Arch Ophthalmol 2011;129:758-66.
71. Tuo J, Ross RJ, Herzlich AA, Shen D, Ding X, Zhou M, et al. A high omega-3 fatty acid diet reduces retinal lesions in a murine model of macular degeneration. Am J Pathol 2009;175:799-807.
72. Hooijmans CR, Pasker-de Jong PC, de Vries RB, Ritskes-Hoitinga M. The effects of long-term omega-3 fatty acid supplementation on cognition and Alzheimer’s pathology in animal models of Alzheimer’s disease: A systematic review and meta-analysis. J Alzheimers Dis 2012;28:191-209.
73. Jicha GA, Markesbery WR. Omega-3 fatty acids: Potential role in the management of early Alzheimer’s disease. Clin Interv Aging 2010;5:45-61.
74. da Silva TM, Munhoz RP, Alvarez C, Naliwaiko K, Kiss A, Andreatini R, et al. Depression in Parkinson’s disease: A double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation. J Affect Disord 2008;111:351-9.
75. Lesperance F, Frasure-Smith N, St-Andre E, Turecki G, Lesperance P, Wisniewski SR, et al. The efficacy of omega-3 supplementation for major depression: A randomized controlled trial. J Clin Psychiatr 2011;72:1054-62.
76. Logan AC. Omega-3 fatty acids and major depression: A primer for the mental health professional. Lipids Health Dis 2004;3:25.
77. Ross BM. Omega-3 polyunsaturated fatty acids and anxiety disorders. Prostaglandins Leukot Essent Fatty Acids 2009;81:309-12.
78. Amminger GP, Schafer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM, et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: A randomized, placebo-controlled trial. Arch Gen Psychiatr 2010;67:146-54.
79. Brenna JT, Diau GY. The influence of dietary docosahexaenoic acid and arachidonic acid on central nervous system polyunsaturated fatty acid composition. Prostaglandins Leukot Essent Fatty Acids 2007;77:247-50.
80. Cole GM, Ma QL, Frautschy SA. Omega-3 fatty acids and dementia. Prostaglandins Leukot Essent Fatty Acids 2009;81:213-21.
81. Duffy EM, Meenagh GK, McMillan SA, Strain JJ, Hannigan BM, Bell AL, et al. The clinical effect of dietary supplementation with omega-3 fish oils and/orcopper in systemic lupus erythematosus. J Rheumatol 2004;31:1551-6.
82. Ross BM, Seguin J, Sieswerda LE. Omega-3 fatty acids as treatments for mental illness: Which disorder and which fatty acid? Lipids Health Dis 2007;6:21.
83. Martins JG. EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: Evidence from a meta-analysis of randomized controlled trials. J Am Coll Nutr 2009;28:525-42.
84. Freeman MP, Hibbeln JR, Wisner KL, Brumbach BH, Watchman M, Gelenberg AJ, et al. Randomized dose-ranging pilot trial of omega-3 fatty acids for postpartum depression. Acta Psychiatr Scand 2006;113:31-5.
85. Adams PB, Lawson S, Sanigorski A, Sinclair AJ. Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression. Lipids 1996;31 Suppl:S157-61.
86. Conklin SM, Manuck SB, Yao JK, Flory JD, Hibbeln JR, Muldoon MF,
et al. High omega-6 and low omega-3 fatty acids are associated with depressive symptoms and neuroticism. Psychosom Med 2007;69:932-4.
87. Lucas M, Mirzaei F, O’Reilly EJ, Pan A, Willett WC, Kawachi I, et al. Dietary intake of n-3 and n-6 fatty acids and the risk of clinical depression in women: A10-y prospective follow-up study. Am J Clin Nutr 2011;93:1337-43.
88. Simopoulos AP. Evolutionary aspects of diet: The omega-6/omega-3 ratio and the brain. Mol Neurobiol 2011;44:203-15.
89. Bourre JM, Bonneil M, Dumont O, Piciotti M, Calaf R, Portugal H, et al. Effect of increasing amounts of dietary fish oil on brain and liver fatty composition. Biochim Biophys Acta 1990;1043:149-52.
90. Bourre JM, Bonneil M, Dumont O, Piciotti M, Nalbone G, Lafont H, et al. High dietary fish oil alters the brain polyunsaturated fatty acid composition. Biochim Biophys Acta 1988;960:458-61.
91. Bhatia HS, Agrawal R, Sharma S, Huo YX, Ying Z, Gomez-Pinilla F, et al. Omega-3fatty acid deficiency during brain maturation reduces neuronal and behavioral plasticity in adulthood. PLoS One 2011;6:e28451.
92. Chung WL, Chen JJ, Su HM. Fish oil supplementation of control and (n-3) fatty acid-deficient male rats enhances reference and working memory performance and increases brain regional docosahexaenoic acid levels. J Nutr 2008;138:1165-71.
93. Bousquet M, Gue K, Emond V, Julien P, Kang JX, Cicchetti F, et al. Transgenic conversion of omega-6 into omega-3 fatty acids in a mouse model of Parkinson’s disease. J Lipid Res 2011;52:263-71.
94. Lim GP, Calon F, Morihara T, Yang F, Teter B, Ubeda O, et al. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J Neurosci 2005;25:3032-40.
95. Hennebelle M, Balasse L, Latour A, Champeil-Potokar G, Denis S, Lavialle M, et al. Influence of omega-3 fatty acid status on the way rats adapt to chronic restraint stress. PLoS One 2012;7:e42142.
96. Ferraz AC, Delattre AM, Almendra RG, Sonagli M, Borges C, Araujo P, et al. Chronic omega-3 fatty acids supplementation promotes beneficial effects on anxiety, cognitive and depressive-like behaviors in rats subjected to a restraint stress protocol. Behav Brain Res 2011;219:116-22.
97. Hammamieh R, Chakraborty N, Gautam A, Miller SA, Muhie S, Waddy E, et al. Transcriptomic analysis of the effects of a fish oil enriched diet on murine brains. PLoS One 2014;9:e90425.
98. Fedorova I, Salem N Jr. Omega-3 fatty acids and rodent behavior. Prostaglandins Leukot Essent Fatty Acids 2006;75:271-89.
99. Calon F, Lim GP, Yang F, Morihara T, Teter B, Ubeda O, et al. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer’s disease mouse model. Neuron 2004;43:633-45.
100. Cole GM, Frautschy SA. Docosahexaenoic acid protects from amyloid and dendritic pathology in an Alzheimer’s disease mouse model. Nutr Health 2006;18:249-59.
101. Shintoa L, Quinna J, Montinec T, Dodgea HH, Woodwarda W, Baldauf-Wagnera S, et al. A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer’s disease. J Alzheimers Dis 2014;38:111-20.
102. Yates CM, Calder PC, Rainger GE. Pharmacology and therapeutics of omega-3 polyunsaturated fatty acids in chronic inflammatory disease. Pharmacol Ther 2014;141:272-82.
103. de Waal H, Stam CJ, Lansbergen MM, Wieggers RL, Kamphuis PJ, Scheltens P, et al. The effect of souvenaid on functional brain network organisation in patients with mild Alzheimer’s disease: A randomised controlled study. PLoS One 2014;9:e86558.
104. Sijben JW, de Wilde MC, Wieggers R, Groenendijk M, Kamphuis PJ. A multi nutrient concept to enhance synapse formation and function: Science behind a medical food for Alzheimer’s disease. OCL 2011;18:267-70.
105. van Wijk N, Broersen L, de Wilde M, Hageman R, Groenendijk M, Sijben JW, et al. Targeting synaptic dysfunction in Alzheimer’s disease by administering a specific nutrient combination. J Alzheimer’s Dis 2014;38:459-79.
106. Wurtman RJ, Ulus IH, Cansev M, Watkins CJ, Wang L, Marzloff G, et al. Synaptic proteins and phospholipids are increased in gerbil brain by administering uridine plus docosahexaenoic acid orally. Brain Res 2006;1088:83-92.
107. Pooler AM, Guez DH, Benedictus R, Wurtman RJ. Uridine enhances neurite outgrowth in nerve growth factor-differentiated PC12 [corrected]. Neuroscience 2005;134:207-14.
108. Sakamoto T, Cansev M, Wurtman RJ. Oral supplementation with docosahexaenoic acid and uridine-59-monophosphate increases dendritic spine density in adult gerbil hippocampus. Brain Res 2007;1182:50-9.
372 Views | 374 Downloads
How to Cite
Aarti, S., and B. Priyanka. “REVIEW ON THERAPEUTIC EFFECTS MEDIATED BY OMEGA-3 FATTY ACIDS IN ALZHEIMER’S DISEASE”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 11, no. 2, Feb. 2018, pp. 54-58, doi:10.22159/ajpcr.2018.v11i2.22435.
Review Article(s)